Adjuvante und neoadjuvante Therapie des Melanoms

Die Behandlung des malignen Melanoms mit (neo-)adjuvanter Therapie stellt einen vielversprechenden Ansatz zur Verminderung von Rezidiven und Metastasierung dar. Gleichzeitig ist aufgrund des Risikos potenzieller Nebenwirkungen vorab eine Nutzen-Risiko-Abwägung unter Berücksichtigung des stadienabhängigen Rezidivrisikos erforderlich. Der Artikel zeigt die aktuelle Studienlage zur adjuvanten und neoadjuvanten Therapie auf.

Abstract

The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.

Schlüsselwörter

Melanom - adjuvant - neoadjuvant - Nutzen-Risiko-Abwägung - pathologische Remission

Keywords

melanoma - adjuvant - neoadjuvant - risk-benefit assessment - pathological remission

• Literatur

• 1 Gershenwald JE, Scolyer RA. Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 2018; 25: 993-994
• 2 Eggermont AMM, Kicinski M, Blank CU. et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. European Journal of Cancer 2024; 211: 114327
• 3 Larkin J, Del Vecchio M, Mandalá M. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res 2023; 29: 3352-3361
• 4 Ascierto PA, Vecchio MD, Merelli B. et al. Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238. Ann Oncol 2023; 34 (02) 656
• 5 Dummer R, Hauschild A, Santinami M. et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020; 383: 1139-1148
• 6 Long GV, Hauschild A, Santinami M. et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2024; 391 (18) 1709-1720
• 7 Amaral T, Ottaviano M, Arance A. et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025; 36 (01) 10-30
• 8 Garbe C, Amaral T, Peris K. et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024. Eur J Cancer 2025; 215: 115153
• 9 Luke JJ, Ascierto PA, Khattak MA. et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. J Clin Oncol 2023; 41 (17) LBA9505
• 10 Luke JJ, Ascierto PA, Khattak MA. et al. Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716. Ann Oncol 2024; 35: 715
• 11 Long GV, Vecchio MD, Hoeller C. et al. Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K. Ann Oncol 2024; 35 (02) 713-714
• 12 Lee R, Rothwell DG, Jackson R. et al. Detection phae II/III trial: Circulating tumour DNA-guided therapy for stage II B/C melanoma after surgical recection. J Clin Oncol 2022; 40 (Suppl. 16)
• 13 Weber JS, Khattak MA, Carlino MS. et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. J Clin Oncol 2024; 42 (17) LBA9512
• 14 Khattak A, Weber JS, Meniawy T. et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. J Clin Oncol 2023; 41 (17) LBA9503
• 15 Bristol Myers Squibb. Corporate news details. 13.02.2025. Accessed April 14, 2025 at: https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-RELATIVITY-098-Trial/default.aspx
• 16 Livingstone E, Forschner A, Hassel JC. et al. Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study. Ann Oncol 2024; 35 (02) S712-S748
• 17 Blank CU, Rozeman EA, Fanchi LF. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24 (11) 1655-1661
• 18 van Akkooi ACJ, Blank C, Eggermont AMM. Neo-Adjuvant Immunotherapy Emerges as Best Medical Practice, and Will Be the New Standard of Care for Macroscopic Stage III Melanoma. Eur J Cancer 2023; 182: 38-42
• 19 Amaria RN, Prieto PA, Tetzlaff MT. et al. Neoadjuvant Plus Adjuvant Dabrafenib and Trametinib Versus Standard of Care in Patients With High-Risk, Surgically Resectable Melanoma: A Single-Centre, Open-Label, Randomised, Phase 2 Trial. Lancet Oncol 2018; 19 (02) 181-193
• 20 Amaria RN, Menzies AM, Burton EM. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019; 20 (07) e378-e389
• 21 Menzies AM, Amaria RN, Rozeman EA. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2021; 27 (02) 301-309
• 22 Blank CU, Versluis JM, Reijers ILM. et al. 3-year relapse-free survival, overall survival and long-term toxicity of (neo)adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma (OpACIN trial). Ann Oncol 2019; 30 (05) v535
• 23 Rozeman EA, Menzies AM, Krijgsman O. et al. 18-months relaps free survival (RSF) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (Ipi) + Nivolumab (Nivo) in stage III melanoma. Ann Oncol 2019; 30 (05) v910
• 24 Versluis JM, Menzies AM, Sikorska K. et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023; 34: 420-430
• 25 Reijers ILM, Menzies AM, van Akkooi ACJ. et al. Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial. Nat Med 2022; 28 (06) 1178-1188
• 26 Kakish H, Xu K, Ahmed FA. et al. Preoperative Therapy in Melanoma: Evolving Perspectives in Clinical Trials. Crit Rev Oncol Hematol 2024; 104193
• 27 Blank CU, Lucas MW, Scolyer RA. et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024; 391 (18) 1696-1708
• 28 Huang AC, Orlowski RJ, Xu X. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019; 25 (03) 454-461
• 29 Long GV, Carlino MS, Au-Yeung G. et al. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. J Clin Oncol 2022; 40 (16)
• 30 Patel SP, Othus M, Chen Y. et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023; 388 (09) 813-823
• 31 Hauschild A, Hassel JC, Ziemer M. et al. Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases. J Clin Oncol 2024; 42 (17) LBA9501
• 32 Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel. Paul-Ehrlich-Institut. List of the Compassionate Use programs of the Paul-Ehrlich Institut. 25.03.2025. Accessed April 14, 2025 at: https://www.pei.de/SharedDocs/Downloads/EN/regulation-en/clinical-trials/list-compassionate-use-programmes.pdf?__blob=publicationFile&v=80
• 33 Amaria RN, Postow M, Burton EM. et al. Neoadjuvant relatlimab and nivoluumab in resectable melanoma. Nature 2022; 611: 155-160